Phase II study of pazopanib with oral topotecan in patients with metastatic and non-resectable soft tissue and bone sarcomas

Overview of attention for article published in British Journal of Cancer, May 2021

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (52nd percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 3 X users

Citations

dimensions_citation: 13 Dimensions

Readers on

mendeley: 13 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 13 publications that cite this research output.

13

The most recent citing publications are shown below. View all 13 publications that cite this research output on Dimensions.

Current Role of Topoisomerase I Inhibitors for the Treatment of Mesenchymal Malignancies and Their Potential Future Use as Payload of Sarcoma-Specific Antibody-Drug Conjugates

Article in Oncology Research and Treatment (November 2023)

Tyrosine kinase inhibitors in osteosarcoma: Adapting treatment strategiesa

Article in Journal of Bone Oncology (November 2023)

Activity of pazopanib in EWSR1-NFATC2 translocation-associated bone sarcoma

Article in Oncoscience (September 2023)